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Popular and scientific accounts of the molecularisation of cancer typically
attribute it to advances in laboratory science, particularly molecular
geneticists. However, historical research has indicated that clinical expertise
input was often vital for advancing such work. The present paper reinforces
that view. Looking in detail at British research into the molecular genetics of
familial cancers during the 1980s and 1990s, it shows that that research, too,
depended on crucial input from family cancer clinics. Moreover, the
development of clinical services for familial cancers was in turn shaped by
the demands of contributing to molecular genetic research. The paper
concludes that accounts of the molecularisation of cancer that suppose a one-
way transfer of knowledge and practice from laboratory to clinic
misrepresent the complex interactions that were involved in molecularising
familial cancers, and that were informed by the particular local and national
circumstances in which they took shape.
Keywords: Molecular oncology; familial cancers; molecularisation; genetic
testing; bioclinical collectives
Introduction
Nowadays, cancer is widely understood to be “a genetic disease” caused by
changes in genes that govern cell growth and multiplication (Wishart 2015;
National Cancer Institute 2017). This understanding is fundamental to what is
now often called “precision oncology” – an approach to cancer treatment that
targets the molecular characteristics of an individual’s tumor. Popular and scientific
accounts of the ascendency of this molecular genetic approach typically attribute it
to advances in laboratory science, in particular the discovery and elucidation of
oncogenes by molecular geneticists (e.g. Bishop 1995; Mukherjee 2011). Several
important studies in the history and sociology of science have significantly
enriched and complicated this narrative, fleshing out the dynamics of discovery,
the role of funding and the disciplinary aspirations that led to the establishment
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of the “oncogene paradigm” as one of the devices by which molecular geneticists
established their claim to be purveyors of fundamental insights, not just into cancer
and its causes, but into human biology more generally (Fujimura 1996; Morange
1997; Scheffler 2019).
Such accounts of the molecularisation of cancer make little reference to clinical
knowledge of cancer or to the practice of clinical oncology, focusing solely on the
molecular genetics laboratory as the site of knowledge production and medical
innovation. However, a growing body of research makes clear that molecularisation
involved far more than a one-way flow of oncogenetic discoveries from the labora-
tory to the clinic. Thus Keating and Cambrosio (2001) have shown that, during the
1980s, clinicians – specifically clinical cytogeneticists –made vital contributions to
the development of oncogene theory through their demonstration that certain
human cancers could be attributed to the occurrence of observable chromosomal
abnormalities. Recent work by de Chadarevian (2020) has situated this work in a
much longer cytogenetic tradition, dating back to the atomic anxieties of the
1950s and persisting into present-day diagnostic practice, that associates cancer
with visible changes in chromosome structure. Nor was cytogenetics the only clini-
cal source of insight into the molecular genetics of cancer. In a study that parallels
many of the findings of the present paper, Necochea (Necochea 2007) has shown
how work that led to the identification and cloning, in the early 1990s, of genes that
predispose to a specific form of familial colon cancer involved a two-way inter-
action between innovative research in molecular genetics and an older tradition
of clinical genetics based on family pedigrees.
These studies are complemented by research that shows the crucial role that
clinical knowledge and practice played in the molecularisation of genetics more
generally. Thus Hogan has shown how, even before molecularisation gained
momentum in the course of the 1980s, clinically-driven cytogenetic research
was crucial in reconfiguring the human genome as a mappable entity, and
thereby in shaping the kinds of questions that molecular geneticists would in
turn come to ask of it (Hogan 2013, 2016). Navon, meanwhile, casts his explana-
tory net even more broadly to show how patients and families, too, have brought
their own knowledge and experience to bear in shaping cytogenetic and more
recently molecular research into a range of disorders (Navon 2019). Their work
confirms and adds detail to broader historical narratives which likewise emphasize
the centrality of clinical expertise and insight to the development of medical
genetic knowledge and practice from the early twentieth century to the present
(Lindee 2005; Comfort 2012). Such studies in turn align with historical research
on the development of “biomedicine” since the mid-twentieth century, which
further underlines the extent to which large areas of medicine, by no means
limited to cancer and genetics, have come to be characterized by a similar insepar-
ability of biological research and clinical practice and a similar interdependency of
clinical discrimination with biological knowledge production (Gaudillière 2002;
Keating and Cambrosio 2003) – a situation that is nowhere better epitomized
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than in the “bioclinical collectives” that today constitute so much of the world of
molecular oncology (Bourret 2005).
The present paper offers a further contribution to this literature on the develop-
ment of biomedicine, and specifically on the molecularisation of cancer. It looks in
detail at work undertaken in Britain during the 1980s and 1990s that aimed both to
isolate genes responsible for a range of familial cancers and to implement medical
interventions that would alleviate or prevent those cancers. Similar work took
place in a number of other countries at the same time, and social scientists have
already argued that, in the case of the Netherlands and France, molecular
genetic research and service provision developed in concert with one another, in
what Stemerding and Nelis call a “co-evolution” process (Bourret, Koch, and Ste-
merding 1998; Palladino 2002; Stemerding and Nelis 2006). The present paper
examines how similar a process unfolded in Britain. It shows how the search for
familial cancer genes and the establishment of family cancer clinical services
were deeply entangled from the start. And in particular, it emphasizes the extent
to which both developments were shaped on the one hand by the peculiar organ-
izational demands of conducting molecular genetic research into rare familial con-
ditions, and on the other by the particular and contingent institutional
circumstances of British oncology and British genetics.
In so doing, this paper adds a further dimension to our understanding of the
relationship between clinic and laboratory in the molecularisation of cancer. In
the case of familial cancers, at least, molecularisation depended not just on intellec-
tual and practical engagement between clinical and molecular geneticists and
oncologists, but on creating the institutional and organizational arrangements
that made that engagement possible. Molecularisation thus remained determinedly
rooted in local and national circumstances, even as it depended increasingly on the
formation of international networks. The following pages document this peculiarly
British story, and in the conclusion I draw out some more general implications.
The paper is based on recursive identification and analysis of a range of publicly
available primary historical sources documenting the development of familial
cancer genetics in the United Kingdom. These included research articles and
reports as well as scientists’ own retrospective writings and a number of interviews
with key actors conducted by other historians. Particularly valuable was the witness
seminar on the history of clinical cancer genetics organized and edited by Tilli
Tansey and colleagues (Jones and Tansey 2013). Data collection and analysis fol-
lowed what was in effect a form of historical snowball sampling. Research began
using sources identified in existing secondary accounts of the history of genetics
and of cancer. Each source was analyzed for the information it provided on familial
cancer genetics in the UK, with particular attention to the kinds of work undertaken,
both research and clinical; the sites where that work was conducted; and the collab-
orations and other relationships that made that work possible. Aworking narrative
was constructed as sources were identified and analyzed, and literature searches
were conducted to identify further sources relevant to the places, people and
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events that featured in that narrative. New sources frequently indicated additional
actors and activities of relevance to the narrative, and sometimes challenged and
prompted significant revisions to that narrative. Searching ceased when new
sources ceased to yield data that significantly added to or amended the narrative
presented in this paper.
The beginnings of cancer family research and practice
It has long been recognized that some families suffer from an unusually high inci-
dence of certain cancers. Despite suspicion on the part of some early twentieth-
century eugenicists that cancer might represent a form of hereditary degeneration,
however, medical and scientific interest in the genetics of cancer remained sporadic
until the 1950s, when a scattering of European and North American geneticists and
oncologists began to take a more sustained interest in so-called “cancer families.”
Underlying this interest was a growing confidence that early surgical intervention
could prevent the onset or progression of cancer in individuals whose family
history indicated that they were at elevated risk of developing the disease. This
approach was exemplified in the work of geneticist Henry Lynch, one of the pio-
neers of US cancer family research. From the 1960s Lynch compiled extended ped-
igrees of families afflicted with hereditary forms of colon, uterine, ovarian and
breast cancer, with a view to identifying individuals at particular risk of developing
malignancies. For those individuals, Lynch advocated regular clinical examination
and surgery where necessary (Cantor 2006; Necochea 2007; Löwy 2010, 171–172).
A parallel development occurred in the UK at St Mark’s Hospital in London,
which specialized in surgical treatment of diseases of the colon and rectum. As
early as the 1920s, the St Mark’s surgeon Percy Lockhart-Mummery began build-
ing a register of patients and pedigrees afflicted with what would eventually come
to be known as familial adenomatous polyposis (FAP), initially for the purpose of
confirming its hereditary character. From the 1950s onwards, as advances in
abdominal surgery made colonectomy safe enough to be used prophylactically,
the registry assumed new importance as a means of tracing relatives, with the
aim of persuading them to undergo diagnostic screening and surgery where
deemed necessary. Now under the care of pathologist Cuthbert Dukes, whom Lock-
hart-Mummery had engaged in 1924 to assist in his endeavors, the case register
developed into a systematic polyposis registry. It also acquired clinical genetics
expertise with the appointment in 1960 of New Zealander Arthur Veale to a joint
position between St Mark’s and Lionel Penrose’s genetics laboratory at University
College London. Through the 1960s and 1970s the St Mark’s Registry would prove
to be a valuable resource for research that aimed to distinguish different forms of
polyposis, understand the factors influencing behind the incomplete penetrance
of the familial polyposis gene, and evaluate the effects of different surgical inter-
ventions (Veale 1960; Palladino 2002, 141–148; Jones and Tansey 2013, 19–24,
88–96).
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Developments at St Mark’s also provided a model for similar initiatives else-
where. General cancer registries had been set up in a number of countries during
the first half of the twentieth century, mainly for epidemiological reasons
(Wagner 1991; Terracini and Zanetti 2003; Löwy 2010, 48–50). The St Mark’s
polyposis registry was distinct in that it focused on a single, strongly familial
cancer, and was associated with a concerted program of surveillance and prophy-
lactic intervention. A similar polyposis registry was established in Sweden in
1957 (Björk et al. 1999), followed in the 1970s by a growing number of national
and regional registries in other Nordic countries, North America and Japan (Bülow
1986). Despite such initiatives, however, research into familial cancers generally
remained localized, both geographically and professionally, through the 1970s.
Most oncologists were unpersuaded that genetics offered any practical insight
into the aetiology of cancer; and insofar as they accepted that some cancers were
strongly familial, they saw little to be gained, either medically or professionally,
by devoting time and effort to such rare forms of disease. Meanwhile, the field
of clinical genetics was largely concerned with calculating the risks and providing
reproductive counseling for birth defects such as Down syndrome and early-onset
genetic disorders such as phenylketonuria and cystic fibrosis. Late-onset, partially
penetrant conditions such as familial cancers therefore offered geneticists little
scope either for research or for clinical practice. As a result, into the 1980s, interest
in familial cancers remained a matter of individual enthusiasm rather than a
common feature of either oncology or clinical genetics departments.
Walter Bodmer, the ICRF, and the introduction of molecular genetics
In 1979 the geneticist Walter Bodmer was appointed director of research at the UK
Imperial Cancer Research Fund (ICRF), at that time the UK’s largest cancer charity,
which supported research in universities and hospitals around the country as well as
running its own research laboratory in London. At first sight, Bodmer was a surpris-
ing choice for the appointment, never having previously ventured into the field of
cancer research. Beneath this apparent mismatch ran a deeper continuity of interest,
however. Bodmer’s predecessor at the ICRF was Michael Stoker, a virologist who
had championed the application of molecular genetic approaches to studying
cancer. Under Stoker’s direction, the ICRF laboratories had made important contri-
butions to the emerging oncogene theory of cancer etiology (Wyke 2013). Bodmer,
for his part, was a distinguished molecular geneticist who, with his wife Julia, had
done pioneering work on the genetics of the human immune system, including
identifying and mapping genes associated with certain autoimmune conditions.
Bodmer was thus well qualified to take forward the ICRF’s role as a leading UK
champion, not just of cancer research, but of molecular genetics (Bodmer 1988).
Following their arrival at ICRF, Walter and Julia initially continued their earlier
research into the genetics of immunity. But Walter also set about familiarizing
himself with the world of cancer. His own first steps into cancer research tapped
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into the current excitement surrounding human oncogenes, and used somatic cell
hybridization – a cytogenetic technique that Bodmer had helped to develop in
his previous research – to map the human oncogene c-abl to chromosome 9 (Heis-
terkamp et al. 1982). At the same time, in surveying the ICRF’s research invest-
ments and the state of cancer research beyond the confines of his own
laboratory, he became aware that a number of oncologists and geneticists scattered
around the country – notably at St Mark’s but also elsewhere – were cultivating an
interest in familial cancers. This interest presented Bodmer with an opportunity to
steer their work in a direction more in line with his own research experience.
As a molecular geneticist with a particular interest in gene mapping, Bodmer was
among the first to observe that so-called restriction fragment length polymorphisms
(RFLPs) – newly discovered molecular markers scattered across human and other
genomes – might provide a powerful new means of mapping genes to their chro-
mosomal locations (Solomon and Bodmer 1979). In 1978 Yuet Wai Kan and
Andrée Dozy had identified a RFLP marker closely linked to the sickle cell
gene, which they suggested might be used for pre-natal diagnosis (Kan and
Dozy 1978). In a commentary he published shortly afterwards with his colleague
Ellen Solomon, Bodmer noted that RFLPs had the potential to open up a much
wider vista of discovery:
one can envisage finding enough markers to cover systematically the whole human
genome… Such a set of genetic markers could revolutionise our ability to study
the genetic determination of complex attributes and to follow the inheritance of
traits that are so far difficult or impossible to study at the cellular level…Association
within families between a defined genetic marker and a trait whose inheritance is not
clearly defined, provides the best evidence, through genetic linkage, for genetic deter-
mination. This powerful approach has so far been limited by the range of genetic
markers available, but restriction-enzyme polymorphisms may soon solve this
problem. (Solomon and Bodmer 1979)
The following year, a group of American molecular geneticists published a land-
mark paper, systematically setting out the feasibility of building a comprehensive
RFLP linkage map of the human genome and using it to map disease genes (Bot-
stein et al. 1980). The methods they outlined were quickly adopted by researchers
around the world, and the following decade would see growing number of human
genes being mapped with increasing precision.
In referring to the potential of RFLPs to study “the genetic determination of
complex attributes,” Solomon and Bodmer suggested that RFLP mapping might
be effective for studying not just the kinds of rare monogenic disorders that had
so far preoccupied clinical geneticists, but also commoner but more complex dis-
orders. His introduction, shortly afterwards, to the work on familial cancers
suggested a way of pursuing that suggestion in the field of cancer. Linkage
mapping depends on being able to follow the occurrence of linked traits and
markers through sufficiently large, well-documented family pedigrees, in order
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to demonstrate non-random segregation from one generation to the next. These
were just the kinds of family records held by the St Mark’s polyposis registry.
For Bodmer, familiar with the techniques of molecular genetics and with the lab-
oratory facilities of the ICRF at his disposal, the St Mark’s registry offered an
unprecedented opportunity to open up an entirely new line of research into the mol-
ecular genetics of cancer.
Building bioclinical research capacity
Up to that point, the St Mark’s polyposis registry had been developed primarily to
meet the standards set by clinical oncologists. The work of case registration and the
construction of cancer family pedigrees had been pursued with enough care to
make it possible to trace and identify family members who might be at risk of
developing cancer and who could be called in for clinical examination and
surgery. It was not clear, however, whether such pedigrees as had so far been col-
lected would be either sufficiently large or sufficiently well characterized to serve in
the search for linkage between RFLP markers and the genes responsible for familial
polyposis. Consequently, Bodmer set about using ICRF funds to ensure that the St
Mark’s FAP work met the standards required, not just for clinical surveillance of the
hospital’s cancer families, but for linkage mapping. In 1984 he funded a new Color-
ectal Cancer Unit, and recruited clinical geneticist Vicky Murday to work there as
an ICRF research fellow. The Unit also took charge of the Polyposis Registry, while
the ICRF paid for the appointment of a research nurse, Kay Neale, to help populate
and maintain it, and to bring new rigor to the registration of cases and the construc-
tion of pedigrees (Jones and Tansey 2013, 24, 28–29).
In case the St Mark’s families were still insufficient for his purposes, Bodmer
also looked to build additional capacity beyond the hospital, and indeed beyond
London. In Manchester, the University had recently appointed the cytogeneticist
David Harnden to direct its Paterson Institute for Cancer Research, where a
Family History Clinic was already in operation for families with breast and
other cancers (Harnden 2004). Harnden quickly teamed up with cancer epidemiol-
ogist Ray Cartwright from the University of Leeds to set up a Cancer Family Study
Group, which would serve as “a discussion group… to bring together all the
people (doctors, scientists, nurses, statisticians and others) who were involved in
the study of families with an increased risk of cancer” (Jones and Tansey 2013,
100). Bodmer too now involved himself in the Study Group, which from early
1984 began to hold meetings at the ICRF laboratories in London as well as in Man-
chester. As with the St Mark’s work, Bodmer also sought to develop the group’s
activities in ways that would favor his own interests as well as those of its foun-
ders. As he put it: “The idea was not that it was a talking shop and a conventional
meeting; the idea was mainly that it should stimulate collaborative studies on
families aimed at finding linkages.” In particular, Bodmer encouraged the
Cancer Family Study Group to share not just clinical and epidemiological
New Genetics and Society 13
knowledge and experience but also tissue samples and pedigrees (Jones and
Tansey 2013, 11–12).
These new networks proved fruitful. In the summer of 1987, Bodmer announced
in a letter to Nature that he and his colleagues had succeeded in demonstrating
linkage of FAP to a RFLP marker on chromosome 5 (Bodmer et al. 1987). The
work of identifying markers and conducting the linkage analysis had been con-
ducted in Bodmer’s own laboratory at the ICRF. But he had depended heavily
on clinical colleagues to identify suitable families and persuade them to provide
tissue samples. The St Mark’s team was crucial to this success: Murday and con-
sultant pathologist Dick Bussey were among the paper’s authors. But Bodmer
had also drawn on the wider cancer family research network he had cultivated
beyond London. Bodmer and his colleagues had examined thirteen families, all
“well characterized with respect to clinical, pathological and pedigree infor-
mation,” of which six had proved to be “informative” (that is, they possessed an
observable form of the linked RFLP). In order to find these families, Bodmer
had worked not only with St Mark’s but also with Tony Ellis at the Gastroenterol-
ogy Unit at the Broadgreen Hospital in Liverpool, plus at least one other unspeci-
fied source (the paper states only that “Most of the families” came from St Mark’s
and the Broadgreen) (Bodmer et al. 1987, 614–615). Without the extended biocli-
nical research network he had cultivated – including oncologists as well as clinical
geneticists and molecular biologists – it is unlikely that Bodmer would have been
able to collect enough pedigrees, patient records and tissue samples to locate the
FAP gene so quickly.
Family cancer clinics
Bodmer’s efforts to build research capacity around familial cancers were not only
fruitful in terms of delivering new biological findings about the genetic basis of
FAP. They also created opportunities to provide new kinds of clinical services.
In 1986 St Mark’s Hospital established a new Family Cancer Clinic with
funding from the ICRF. The Clinic was staffed by clinical geneticist Joan Slack
and a genetic research nurse, Christina Harocopos, both of whom worked
closely with Vicky Murday in the Colorectal Cancer Unit and Polyposis Registry.
The work of the new clinic was not confined to FAP, however, covering all kinds of
colorectal cancer seen by the Hospital. Epidemiological research conducted there in
the early 1970s had shown that relatives of patients with all kinds of colorectal
cancer faced some degree of elevated risk of developing the condition, even in
the absence of any previous family history of cancer. ICRF now funded a research
fellow to re-analyse these findings and devise a method of estimating any individ-
ual’s risk on the basis of what could be discovered of their family history. Using this
method, the staff of the Clinic now began tracing the relatives of all patients pre-
senting with colorectal cancers and, if deemed advisable, counseling them about
their risk and offering to screen them for malignancies (Houlston et al. 1990;
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Jones and Tansey 2015, 50–52, 79–80). Statistics from the first few years of the
Clinic’s operation indicated that these measures were effective in facilitating
early detection of undiagnosed cases of cancer. At the same time, the Clinic ident-
ified and described a number of families with what was just coming to be recog-
nized as another strongly familial cancer syndrome – so called Lynch syndrome
or hereditary non-polyposis colon cancer (HNPCC) (Itoh et al. 1990).
Importantly, the St Mark’s Family Cancer Clinic was seen as breaking new
ground, not just in the field of oncology, but also in clinical genetics. Shortly
after its inception, it officially became part of North East Thames Regional Genetics
Service (Houlston et al. 1990). Over the previous decade or so, several of the
Regional Health Boards that oversaw the delivery of hospital and consultant ser-
vices under the National Health Service (NHS) had established genetics services
run by clinical geneticists and genetic counselors (Coventry and Pickstone 1999;
Leeming 2005; Harper 2019). Much of the work of these clinicians was taken up
with prenatal diagnosis and counseling for sporadic birth defects such as Down
syndrome and neural tube defects, using amniocentesis and either cytogenetic or
biochemical tests. But it also included familial risk assessment and reproductive
counseling for a growing range of rare monogenic disorders including phenylketo-
nuria, cystic fibrosis and muscular dystrophy. It had not previously included
complex, late onset disorders such as cancer, however. The incorporation of the
St Mark’s clinic into the Regional Genetics Service thus marked a significant
expansion in what services clinical geneticists could be expected to provide. At
the same time, it represented an important endorsement by the Region’s clinical
geneticists that the activities of the St Mark’s clinic were in line with the expec-
tations of confidentiality, consent and non-directive counseling that were central
to the identity and practice of clinical genetics as a specialism (Kingston 1989;
cf. Stern 2012).
The St Mark’s Family Cancer Clinic also served as a model for developments
elsewhere in the UK. Between the mid-1980s and the early 1990s, family cancer
clinics were set up in collaboration with regional genetics services in Leeds
(whence Vicky Murday moved from St Mark’s), Newcastle, Manchester, Cardiff
and Oxford. The ICRF actively supported these developments. “[H]aving seen
also what could be done at St Mark’s,” recalled Bodmer, “in the ICRF we
thought there was a case for trying to create places where cancer family studies
and genetics would be done in association with oncology units.” The ICRF accord-
ingly provided financial assistance, “generally to fund someone like a nurse, who
could be involved in helping with the aspects of the cancer family clinic that went
alongside what the genetic consultant would do” (Jones and Tansey 2013, 58–59).
In connection with local oncology units, the regional genetics services thus began
to take a growing role in providing care and counseling for those affected by famil-
ial cancers. They also saw an increasingly wide range of cancers: while the kinds of
cases seen at the St Mark’s clinic were constrained by the hospital’s specialist focus
on diseases of the lower bowel, family cancer services based elsewhere took a
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wider view, looking beyond FAP and HNPCC to encompass other hereditary
cancers including Von Hippel-Lindau disease, Li Fraumeni syndrome, neurofibro-
matosis, and familial forms of breast cancer (Fraser 1999; Harnden 2004; Jones and
Tansey 2013, 26, 55–56, 58–60, 100–101, 108).
Synergy of research and clinical care
Clearly the new family cancer clinics were not set up solely with the aim of deli-
vering clinical services. On the contrary, as one geneticist recalled, they “were
largely clinics that were set up for research, to get the families, and to research
the families” (Jones and Tansey 2013, 53). But at the same time, efforts to identify
families for research purposes also identified new opportunities to expand clinical
service provision. In the case of Von Hippel-Landau disease, for instance, clinical
geneticist Eamonn Maher recalled that
the initial driver to setting up new clinical services for VHL patients in Cambridge
was the fact that we were starting a research study. We were collecting families for
linkage studies and we needed to evaluate affected and apparently unaffected
members of the family to see whether they were sub-clinically affected. (Jones and
Tansey 2013, 63–64)
Using these families, Maher would first confirm the recent mapping of Von Hippel-
Lindau disease to chromosome 3p (Maher et al. 1990), then make a major contri-
bution to the international collaboration that succeeded in identifying the gene itself
three years later (Latif et al. 1993). But the search for families also identified needs
that the genetic services had not so far met:
As we went round the country collecting VHL families, we found that most were not
under surveillance and they needed local follow-up and screening and, more often
than not, that was done through a local geneticist. So that was my experience of
how VHL clinics developed. (Jones and Tansey 2013, 63–64)
Research stimulated the growth of clinical services, as much as clinical services
helped to support research.
Staff from the family cancer clinics also became increasingly involved in the
growing number of international research collaborations that were being set up
to map familial cancers. Researchers from Iceland and possibly Newfoundland
had attended the Cancer Family Study Group from early in its existence (Jones
and Tansey 2013, 11–12). But such interactions intensified dramatically from the
late 1980s, as efforts to map and clone the genes involved in familial cancers accel-
erated. UK researchers were drawn into the International Collaborative Group on
HNPCC (ICG-HNPCC), for instance, following its establishment by Nether-
lands-based clinician Hans Vasen in 1990 (Lynch et al. 2003). These included gen-
eticists John Burn, who ran the family cancer clinic in Newcastle, and Tim Bishop,
who headed the ICRF research laboratory in Leeds. Burn and Bishop also provided
pedigrees and samples to American molecular geneticist Richard Kolodner, who
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used them in his successful identification of the MSH2 mismatch repair gene in
HNPCC (Fishel et al. 1993; Jones and Tansey 2013, 56–57). UK researchers
also played a pivotal role in the Breast Cancer Linkage Consortium set up in
1989 to coordinate European efforts to map and isolate genes involved in familial
breast cancer (Bishop et al. 1995; Dalpé et al. 2003, 206–208).
Clinical geneticists’ familiarity with new molecular genetic research techniques
in turn fed back into the clinical services they were able to offer. When the first
family cancer clinics were established in 1986, genetic counseling and referral
for screening still depended on risk calculations based on family history.
Bodmer’s identification of a linked RFLP marker for FAP only a year or so later
made it possible to determine with a much higher degree of certainty which
members of some (though by no means all) FAP families carried a deleterious
allele – and to do so, moreover, from an early age, before the onset of the
polyps that were previously the principal means of identifying at-risk family
members (Houlston, Slack, and Murday 1990; MacDonald et al. 1992; Palladino
2002, 149–50). The new molecular test transformed that practice, as John Burn
recalled: “the minute we got that marker [i.e. FAP], we then kicked into predictive
testing in our dominant families generally” (Jones and Tansey 2013, 57). With the
cloning and characterization, from the early 1990s, of genes responsible for FAP,
HNPCC, some familial breast cancers and other familial cancers, the use of mol-
ecular tests in family cancer clinics expanded rapidly. The publicity surrounding
the isolation of the BRCA breast cancer genes, in particular, precipitated a rapid
rise in demand for such tests (Jones and Tansey 2013, 53–54).
In effect, the synergy between research and service provision in the work of the
family cancer clinics created a positive feedback loop between biomolecular
science and clinical practice. The access to cases and families afforded by the
clinics greatly facilitated research into the molecular correlates and causes of famil-
ial cancers; while involvement in that research facilitated the introduction of new
molecular tests into clinical practice. The availability of these new tests in turn
brought more cases and families into the clinics, enabling further research into par-
ticular mutations and their pathological effects. From their first tentative beginnings
in the mid-1980s, the family cancer clinics expanded and spread to become, by the
end of the 1990s, a key component both in the NHS’s clinical genetics service and
in the growth of molecular genetic research around the UK.
Differentiation among family cancers
At the same time, as research and service provision for familial cancers expanded
and diversified to include an increasingly wide range of conditions, so differences
became increasingly apparent in the collaborations that formed around different
cancers. Use of linkage analysis to map family cancer genes depended on being
able to determine with a high degree of certainty which members of an affected
family carried the pathogenic gene variant and which did not. In many cases,
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geneticists had to rely in the first instance on clinical oncologists, who had the diag-
nostic skills to make such judgements. Hence the efforts of Bodmer and others to
ensure that the new family cancer clinics had good connections to local oncology
units. As one geneticist recalled: “the evolution of cancer genetics services… [was]
coupled early on to linkage studies where clinical phenotyping was very important”
(Jones and Tansey 2013, 65). Just how heavily linkage studies depended on clinical
phenotyping varied markedly from on condition to another, however.
Reliance on clinical oncologists’ diagnostic abilities was particularly important
in work on HNPCC. The phenotypic expression of this condition varies signifi-
cantly from one case to another, making it difficult to distinguish individuals and
families with HNPCC from sporadic cases of colon and other cancers. Efforts to
map and isolate the genes responsible for HNPCC thus involved particularly
close collaboration between clinical oncologists and clinical and molecular geneti-
cists. This was evident for instance in the constitution of the ICG-HNPCC, one of
the key early achievements of which was the agreement and adoption of a set of
diagnostic criteria – the so-called Amsterdam principles – by which oncologists
could identify cases with sufficient reliability to permit genetic linkage analysis
(Necochea 2007, 272–274). This alliance remained important even after a
number of HNPCC genes were mapped then isolated in the early 1990s, and mol-
ecular genetic research moved to identifying and characterizing specific variants of
those genes. On the one hand, geneticists continued to depend on clinical oncolo-
gists to identify cases for molecular testing and further investigation. On the other
hand, clinicians were concerned that the tight diagnostic criteria that best served the
purposes of genetic research might tend to exclude some cases who would benefit
from clinical attention. The ICG-HNPCC therefore continued to provide a forum
where geneticists and oncologists could work together to update the Amsterdam
principles in line with the changing needs of research and clinical care (Vasen
et al. 1999; Lynch et al. 2003).
In the case of FAP, by contrast, clinical diagnosis was generally much more
straightforward, based on the characteristic presence of large numbers of polyps
in the colon, with only limited scope for further clinical differentiation thereafter.
Consequently, as efforts to map then clone the FAP gene progressed, clinical oncol-
ogists found themselves increasingly peripheral to the work of genetic research and
testing, as their role was reduced to simply identifying suitable cases for referral to
the family cancer clinic. Instead, their own interests came to focus more closely on
the practicalities of clinical prevention and treatment. As early as 1985 the St
Mark’s surgeons had convened an international meeting at Leeds Castle to consider
the clinical implications of the new genetic research for diagnosing and treating
FAP (Jones and Tansey 2013, 78–79), and over time, the Leeds Castle Group
grew to become the main international forum where clinical oncologists could
share their interest and experience with this condition. This focus on clinical man-
agement in turn brought the Leeds Castle Group into increasingly close alignment
with clinical oncologists in the ICG-HNPCC, and in 2005 the two organizations
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joined to form the International Society for Gastrointestinal Hereditary Tumors
(InSiGHT).
Finally, in the case of breast cancer, researchers quickly found that there was
little clinical difference between familial and sporadic cases of the disease. Familial
forms of breast cancer were best distinguished from sporadic cases simply on
grounds of family history, and clinical geneticists had little need of input from clini-
cal oncologists beyond the initial diagnosis of a breast tumor. As a result, clinical
oncologists were largely absent from both local and international efforts to map and
identify the genes responsible. By the later 1990s, however, it was apparent that the
genes so identified accounted for only a small proportion of familial cases. Conse-
quently, a separate and more inclusive collaboration had to be established with
European Commission funding to draw up guidelines for identifying and following
up women at high risk of inherited breast cancer (Møller et al. 1999; Jones and
Tansey 2013, 79).
If clinical oncologists found themselves aligning in different ways around differ-
ent kinds of familial cancer research, the geneticists who ran the family cancer
clinics were meanwhile confronting new clinical concerns of their own. With the
rapid growth in demand for new molecular tests, geneticists faced growing pressure
to routinize and quality assure their procedures. The laboratories they had used to
map and clone cancer genes had performed well enough for research purposes. But
they could not always be relied upon to maintain the strict chains of custody
required for routine clinical testing. As one clinical geneticist put it,
I think the problem was the provenance of the blood and the results; you couldn’t trust
it. Until you could go through an NHS screening laboratory with its set-up, you
always had a little degree of uncertainty of what you were getting. (Jones and
Tansey 2013, 69–70, 72)
Geneticists’ clinical concerns therefore came to focus on aligning cancer genetic
tests more closely with the kinds of procedural standards that obtained elsewhere
in genetic laboratory services, and with developing “more standardized care
package[s] and screening programme[s]” for those individuals found to be at risk
(Jones and Tansey 2013, 65). This led to changes in the constitution of the
Cancer Family Study Group. Initially a very multi-disciplinary body, reflecting
the collaborative nature of efforts to map the genes for FAP and other familial
cancers, over the course of the 1990s it became increasingly focused on the con-
cerns of clinical geneticists, while the clinical oncologists redirected their activities
around organizations like the ICG-NHPCC. “Gradually through the early 1990s the
[Cancer Family Study] group became more and more genetics-oriented,” recalled
one geneticist (Jones and Tansey 2013, 14–15); and by the end of the decade it
was “transforming itself into more of a service type organization” in the words
of another (Jones and Tansey 2013, 65). In 2000 the Cancer Family Study
Group renamed itself the Cancer Genetics Group and affiliated to the British
Society for Human Genetics.
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Discussion
From the very beginning, efforts to map and isolate genes associated with familial
cancers depended on a two-way exchange of knowledge and expertise between the
laboratory and the clinic. Clinical involvement was not confined to providing access
to patient records and samples. Molecular geneticists, clinical geneticists, and
oncologists all worked together to ensure that recruitment, diagnosis and documen-
tation of patients and families met the standards required for both molecular genetic
research and clinical care; and all made essential contributions to the new knowl-
edge that issued from their collaborative efforts. As a result, as new genetic tests
become available, they were introduced into clinical settings that were already con-
figured and primed to make sense of and act upon the information those tests
provided. The molecularisation of familial cancers in the UK was a process of
“co-evolution,” involving “changing configurations of actors, routines, rules, insti-
tutions and technologies,” as Stemerding and Nelis have already observed in the
case of FAP testing in the Netherlands (Stemerding and Nelis 2006).
Indeed, those configurations changed continuously throughout the process, from
Bodmer’s initial efforts to turn the St Mark’s polyposis registry into a viable source
of molecular genetic data, to the introduction and routinization of molecular tests
not just for FAP but for other familial cancers including HNPCC and familial
breast cancer. Moreover, while there were clearly many points of commonality
between these different cancers, the precise configurations and dynamics of
change also differed between them, depending on the particular clinical and bio-
logical questions each cancer posed. This is perhaps one of the key lessons to
come out of the present study. It is not just that the molecularisation of familial
cancers depended on clinical as well as laboratory knowledge and expertise.
More than that, the precise configuration of actors and other resources was different
from one cancer to another.
This is worth bearing in mind. We already know that the kinds of bioclinical col-
lectives that formed around the implementation of molecular genetic tests in fields
as far apart as cancer and mental illness are significantly different from one another
(Rabeharisoa and Bourret 2009). What the present paper shows is that, even with
conditions so apparently similar as familial cancers, molecularisation is not uniform
and universal, but differentiated and local. We might surmise that this is at least
partly a corollary of the pursuit of precision in molecular oncology: to the extent
that the molecularisation of familial cancers aimed to discriminate ever more pre-
cisely between diseases, between symptomatic patients and asymptomatic carriers,
and eventually between the bearers of growing numbers of chromosomal abnorm-
alities and point mutations, so the particular combinations of clinical and biological
knowledge and skill needed to achieve such discrimination became ever more
specific and more specialized around particular conditions. Precision oncology,
in other words, might actually be localized in proportion to the extent to which it
achieves precision.
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If that much is speculation, it is clear that the co-evolutionary process of mole-
cularising familial cancers did not follow the same path for all cancers. It is also
clear that it differed significantly in the UK, especially in its clinical aspects,
from other countries that we know about. Thus in the Netherlands, according to
Stemerding and Nelis, clinical geneticists did not become involved in the molecu-
larisation of familial cancers until molecular tests for those cancers became avail-
able. Up to that point, collaboration around familial cancers was confined to
molecular geneticists and oncologists. Consequently, the advent of molecular
testing marked an abrupt shift in the way that patients were treated. Up until that
point, clinical practice was dominated by oncologists’ activist concern with early
intervention in the form of surveillance and preventive surgery: what Stemerding
and Nelis call a “regime of prevention.” Only once clinical geneticists became
involved in delivering molecular tests did the less directive forms of counseling
and decision-making clinical genetic practice – what Stemerding and Nelis call a
“regime of autonomy” – come to prevail (Stemerding and Nelis 2006). A similarly
late involvement of clinical geneticists appears to have occurred in France and
Denmark (Bourret, Koch, and Stemerding 1998). By contrast, as we have seen,
in the UK clinical geneticists were involved in molecular research into familial
cancers from very early in the process. Indeed, the clinical aspects of that
process quickly became institutionalized within the NHS regional genetics ser-
vices. As a result, a regime of autonomy – including non-directive counseling
for conditions such as familial risk of breast cancer – became the norm for familial
cancers in the UK well before molecular tests became available.
Clearly, accounts of the molecularisation of cancer that suppose a one-way
transfer of knowledge and practice from laboratory to clinic fall far short of cap-
turing the complex interactions that were involved in molecularising familial
cancers, from the production of new molecular genetic knowledge to the
implementation of that knowledge in clinical practice. Nor would any single nar-
rative that would apply to all kinds of cancer capture that complexity; molecular-
isation is a local process – localized around particular medical conditions as well
as around particular places – even while it involves circulation and exchange
across localities. To understand, molecularisation, we need to grasp the extent to
which it is localized. There is clearly room for much more research to comprehend
the significance both of locality and of circulation in the molecularisation of cancer
and of medicine more generally.
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